The results of a recently published national survey - co-authored by several HOPA members - have helped paint a clearer picture of the current landscape of oncology stewardship in the United States.

In order to gain greater knowledge about the state of oncology stewardship, HOPA distributed a survey to 675 of its members between September 9, 2022 and October 9, 2022. The survey results found that, though most organizations have adopted general oncology stewardship practices, significantly fewer have established formalized oncology stewardship programs due to a number of frequently cited barriers. The article concludes with a call for formalized oncology stewardship programs in the United States that aid in the value, quality, and safety of cancer care.

The full results of the national survey are now published in the Journal of Oncology Pharmacy Practice.


Authors: Marisela Tan Banez, Sol Atienza, Allison Butts, Megan Derba, Katie Dicke, Kimberly Haverstick, Bernadette B. Heron, Sarah K. Cimino, Matthew Shane Loop, Shannon Hough, Julianna A. Merten, Donald C. Moore, Vishal Shah, Kate D. Taucher, Junyu Matt Zhang, and Zahra Mahmoudjafari.

Read the full abstract here

Pharmacist with technology
HOPA News Late Breaking News

Late-Breaking HOPA News: AI Integration in Pharmacy

Aracely Sosa, PharmD; Katelyn Toeniskoetter, PharmD, BCOP; and Pearl Abraham, PharmD, BCPS, BCOP, dive into the basics and beyond of AI integration in pharmacy.

Diffuse large B-cell lymphoma
HOPA News Late Breaking News

Late-Breaking HOPA News: The Emerging Use of Bispecific Antibodies with Chemotherapy in Diffuse Large B-Cell Lymphoma

Katelynn Granger, PharmD, BCOP, and Matthew Warrick, PharmD, BCPS, BCOP, dive into the emerging use of bispecific antibodies with chemotherapy in diffuse large B-cell lymphoma.

Woman diagnosing breast cancer
HOPA News Late Breaking News

Late-Breaking HOPA News: Fam-trastuzumab deruxtecan-nxki for HER2 Ultralow Metastatic Breast Cancer

The ability of fam-trastuzumab deruxtecan-nxki to treat breast cancer patients with HER2 IHC 0 with positive membrane staining up to IHC 3+ has changed the treatment paradigm for metastatic disease.